Sutro Biopharma (STRO) Accumulated Expenses (2017 - 2025)

Sutro Biopharma has disclosed Accumulated Expenses across 9 years of filings, most recently posting $12.6 million for Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $12.6 million, down 59.69% year-over-year; the trailing twelve-month figure through Dec 2025 was $12.6 million (down 59.69% YoY), and the FY2025 annual result was $12.6 million, down 59.69% from the prior year.
• Accumulated Expenses came in at $12.6 million for Q4 2025 at Sutro Biopharma, down from $13.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $38.5 million in Q4 2023 to a low of $4.5 million in Q1 2021.
• The 5-year median for Accumulated Expenses is $11.7 million (2025), against an average of $15.3 million.
• Across the five-year window, Accumulated Expenses jumped 204.58% in 2024 and tumbled 69.39% in 2025, its largest moves.
• Sutro Biopharma's Accumulated Expenses stood at $8.4 million in 2021, then soared by 56.42% to $13.1 million in 2022, then surged by 192.75% to $38.5 million in 2023, then dropped by 18.77% to $31.2 million in 2024, then slumped by 59.69% to $12.6 million in 2025.
• The last three Accumulated Expenses figures came in at $12.6 million (Q4 2025), $13.2 million (Q3 2025), and $11.8 million (Q2 2025), per Business Quant data.